JP2013536236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536236A5 JP2013536236A5 JP2013526085A JP2013526085A JP2013536236A5 JP 2013536236 A5 JP2013536236 A5 JP 2013536236A5 JP 2013526085 A JP2013526085 A JP 2013526085A JP 2013526085 A JP2013526085 A JP 2013526085A JP 2013536236 A5 JP2013536236 A5 JP 2013536236A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- neoplastic disease
- cancer
- antibody
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 8
- 230000001613 neoplastic Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 3
- 108090001123 antibodies Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims 2
- 210000000601 Blood Cells Anatomy 0.000 claims 1
- 208000005024 Castleman Disease Diseases 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Claims (12)
- ヒト対象において腫瘍性疾患を治療するための薬剤の製造における、抗IL−1α抗体の使用。
- 請求項1に記載の使用において、前記抗IL−1α抗体がモノクローナル抗体であることを特徴とする、使用。
- 請求項2に記載の使用において、前記モノクローナル抗体がMABp1であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患が結直腸癌であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患がKRAS突然変異癌であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患がEBV感染に関連することを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患が鼻咽頭癌であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患が肺癌であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患が、血液細胞新生物が関連する非癌性状態であることを特徴とする、使用。
- 請求項1に記載の使用において、前記腫瘍性疾患がキャッスルマン病であることを特徴とする、使用。
- ヒトの癌患者の腫瘍のサイズを縮小するための薬剤の製造における、抗IL−1α抗体の使用。
- 請求項11に記載の使用において、前記ヒトの癌患者が、化学療法、放射線療法または生物学的薬剤での治療後に癌が進行した患者であることを特徴とする、使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016100753A JP6917681B2 (ja) | 2010-08-23 | 2016-05-19 | 腫瘍性疾患のための治療 |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37609710P | 2010-08-23 | 2010-08-23 | |
US61/376,097 | 2010-08-23 | ||
US40675910P | 2010-10-26 | 2010-10-26 | |
US61/406,759 | 2010-10-26 | ||
US41118310P | 2010-11-08 | 2010-11-08 | |
US61/411,183 | 2010-11-08 | ||
US201161480635P | 2011-04-29 | 2011-04-29 | |
US61/480,635 | 2011-04-29 | ||
PCT/US2011/048747 WO2012027324A2 (en) | 2010-08-23 | 2011-08-23 | Treatment for neoplastic diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016100753A Division JP6917681B2 (ja) | 2010-08-23 | 2016-05-19 | 腫瘍性疾患のための治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013536236A JP2013536236A (ja) | 2013-09-19 |
JP2013536236A5 true JP2013536236A5 (ja) | 2015-04-30 |
JP6241932B2 JP6241932B2 (ja) | 2017-12-06 |
Family
ID=45594256
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013526085A Active JP6241932B2 (ja) | 2010-08-23 | 2011-08-23 | 腫瘍性疾患のための治療 |
JP2016100753A Active JP6917681B2 (ja) | 2010-08-23 | 2016-05-19 | 腫瘍性疾患のための治療 |
JP2019125907A Active JP7316120B2 (ja) | 2010-08-23 | 2019-07-05 | 腫瘍性疾患のための治療 |
JP2021096528A Pending JP2021138750A (ja) | 2010-08-23 | 2021-06-09 | 腫瘍性疾患のための治療 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016100753A Active JP6917681B2 (ja) | 2010-08-23 | 2016-05-19 | 腫瘍性疾患のための治療 |
JP2019125907A Active JP7316120B2 (ja) | 2010-08-23 | 2019-07-05 | 腫瘍性疾患のための治療 |
JP2021096528A Pending JP2021138750A (ja) | 2010-08-23 | 2021-06-09 | 腫瘍性疾患のための治療 |
Country Status (17)
Country | Link |
---|---|
US (3) | US10294296B2 (ja) |
EP (3) | EP2608808B1 (ja) |
JP (4) | JP6241932B2 (ja) |
KR (6) | KR20210128021A (ja) |
CN (3) | CN107252484A (ja) |
AU (1) | AU2011293554B9 (ja) |
DK (1) | DK2608808T3 (ja) |
ES (2) | ES2856723T3 (ja) |
IL (2) | IL262856B (ja) |
MX (1) | MX342776B (ja) |
NZ (1) | NZ607472A (ja) |
PH (1) | PH12016500578A1 (ja) |
PT (1) | PT2608808T (ja) |
RU (2) | RU2679119C2 (ja) |
SG (1) | SG187853A1 (ja) |
WO (1) | WO2012027324A2 (ja) |
ZA (1) | ZA201301420B (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2582391T (pt) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Tratamento da artrite |
DK2608808T3 (en) | 2010-08-23 | 2017-04-24 | Xbiotech Inc | TREATMENT OF NEOPLASTIC DISEASES |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
KR102039198B1 (ko) | 2011-09-23 | 2019-10-31 | 엑스바이오테크, 인크. | 악액질 치료법 |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
US20170260285A1 (en) * | 2014-11-24 | 2017-09-14 | University Of Iowa Research Foundation | Methods for treating cancer |
JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク,インコーポレイテッド | 化膿性汗腺炎の処置 |
US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
US5034316A (en) | 1987-03-30 | 1991-07-23 | The Regents Of The University Of California | In vitro human monoclonal IgG rheumatoid factor autoantibody |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2049342A1 (en) | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
US5407431A (en) | 1989-07-11 | 1995-04-18 | Med-Design Inc. | Intravenous catheter insertion device with retractable needle |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JPH08502300A (ja) | 1992-10-14 | 1996-03-12 | スターリング ウィンスロップ アイエヌシー. | 治療および診断像形成組成物および方法 |
ES2159529T5 (es) | 1993-03-05 | 2011-03-09 | Bayer Corporation | Anticuerpos monoclonales humanos anti-tnf alfa. |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9405021D0 (en) | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
GB9509620D0 (en) | 1995-05-12 | 1995-07-05 | Nat Blood Authority | Transepithelial transport of molecular species |
US6140470A (en) | 1995-06-30 | 2000-10-31 | Yale University | Human monoclonal anti-tumor antibodies |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
US20030040617A9 (en) | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
DK1200479T3 (da) * | 1999-08-09 | 2006-05-15 | Emd Lexigen Res Ct Corp | Multiple cytokin-antistof-komplekser |
DE19943790C2 (de) | 1999-09-13 | 2001-11-15 | Ericsson Telefon Ab L M | Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten |
US6380129B1 (en) | 1999-11-02 | 2002-04-30 | Richard J. Kraemer | Enhanced materials for treatment of contamination |
US6811788B2 (en) * | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
US6623736B2 (en) | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
AU2007202323C1 (en) | 2000-06-29 | 2012-04-12 | Abbvie Inc. | Dual specificity antibodies and methods of making and using |
WO2002033094A1 (fr) | 2000-10-19 | 2002-04-25 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps inhibant l'activite vplf |
US20030026806A1 (en) | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
US7348003B2 (en) * | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
US7211602B2 (en) | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
CN104178491B (zh) | 2002-09-06 | 2018-07-03 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
JP4450644B2 (ja) | 2003-03-03 | 2010-04-14 | 日本化薬株式会社 | Amf類を有効成分とする医薬製剤 |
US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
KR100493102B1 (ko) | 2003-06-30 | 2005-06-02 | 삼성전자주식회사 | 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치 |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US7799327B2 (en) | 2003-12-24 | 2010-09-21 | Henry John Smith | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment |
US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
WO2006001967A2 (en) | 2004-05-25 | 2006-01-05 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs in the treatment of cancer |
US20050276807A1 (en) | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
WO2006036936A2 (en) | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
KR101281501B1 (ko) * | 2004-12-09 | 2013-07-15 | 얀센 바이오테크 인코포레이티드 | 항인테그린 면역 컨쥬게이트, 방법 및 용도 |
US8187817B2 (en) | 2005-08-02 | 2012-05-29 | Xbiotech, Inc. | Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
JP5312028B2 (ja) | 2005-09-28 | 2013-10-09 | サイトス バイオテクノロジー アーゲー | インターロイキン−1コンジュゲート及びその使用 |
WO2007120828A1 (en) | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of il-i antibodies for treating ophthalmic disorders |
ES2384278T3 (es) | 2006-05-15 | 2012-07-03 | Xbiotech, Inc | IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas |
US20110008282A1 (en) | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
AU2007252990B2 (en) * | 2006-05-22 | 2011-10-27 | Xbiotech Inc. | Treatment of cancer with anti-IL-1alpha antibodies |
RS53168B (en) | 2006-05-30 | 2014-06-30 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
WO2008082651A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Dual-specific il-1a/ il-1b antibodies |
EP2265125B1 (en) | 2008-04-15 | 2019-08-14 | SARcode Bioscience Inc. | Topical lfa-1 antagonists for use in localized treatment of immune related disorders |
PL2285409T3 (pl) | 2008-05-30 | 2016-10-31 | Przeciwciała il-1 alfa | |
WO2010030979A2 (en) * | 2008-09-12 | 2010-03-18 | Xbiotech, Inc. | Targeting pathogenic monocytes |
MX2011003691A (es) | 2008-10-16 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. |
EP2391652A4 (en) | 2009-01-29 | 2013-01-02 | Abbott Lab | IL-1 BINDING PROTEINS |
FR2945396A1 (fr) * | 2009-05-07 | 2010-11-12 | St Microelectronics Grenoble 2 | Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce |
EP2488201A4 (en) | 2009-10-15 | 2013-12-25 | Abbvie Inc | IL-1 BINDING PROTEINS |
JP5944382B2 (ja) | 2010-06-03 | 2016-07-05 | アッヴィ バイオテクノロジー リミテッド | 汗腺膿瘍(hs)の治療のための使用および組成物 |
PT2582391T (pt) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Tratamento da artrite |
DK2608808T3 (en) | 2010-08-23 | 2017-04-24 | Xbiotech Inc | TREATMENT OF NEOPLASTIC DISEASES |
RU2013115927A (ru) | 2010-09-10 | 2014-10-20 | Апексиджен, Инк. | АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ |
TW201307388A (zh) | 2010-12-21 | 2013-02-16 | Abbott Lab | Il-1結合蛋白 |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
US20120251548A1 (en) | 2011-04-01 | 2012-10-04 | Xbiotech, Inc. | Treatment of Dermatological Pathologies |
JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
KR102039198B1 (ko) | 2011-09-23 | 2019-10-31 | 엑스바이오테크, 인크. | 악액질 치료법 |
US20130195877A1 (en) | 2012-01-31 | 2013-08-01 | Xbiotech, Inc. | Treatment of cachexia by targeting interleukin-1 beta |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
AU2013327501B2 (en) | 2012-10-04 | 2018-08-09 | Xbiotech Inc. | Treating vascular disease and complications thereof |
CN104684581A (zh) | 2012-10-04 | 2015-06-03 | 埃克斯生物科技公司 | 精神病症的治疗 |
JP6371758B2 (ja) | 2013-03-12 | 2018-08-08 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
US20150024031A1 (en) | 2013-07-17 | 2015-01-22 | Baxter International Inc. | Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent |
SG11201609487QA (en) | 2014-06-03 | 2016-12-29 | Xbiotech Inc | Compositions and methods for treating and preventing staphylococcus aureus infections |
JP7145162B2 (ja) | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク,インコーポレイテッド | 化膿性汗腺炎の処置 |
-
2011
- 2011-08-23 DK DK11820492.4T patent/DK2608808T3/en active
- 2011-08-23 RU RU2017112088A patent/RU2679119C2/ru active
- 2011-08-23 CN CN201710452010.2A patent/CN107252484A/zh active Pending
- 2011-08-23 PT PT118204924T patent/PT2608808T/pt unknown
- 2011-08-23 JP JP2013526085A patent/JP6241932B2/ja active Active
- 2011-08-23 NZ NZ607472A patent/NZ607472A/en unknown
- 2011-08-23 EP EP11820492.4A patent/EP2608808B1/en active Active
- 2011-08-23 CN CN2011800476614A patent/CN103153340A/zh active Pending
- 2011-08-23 KR KR1020217032773A patent/KR20210128021A/ko not_active IP Right Cessation
- 2011-08-23 ES ES18199427T patent/ES2856723T3/es active Active
- 2011-08-23 KR KR1020207002089A patent/KR102314003B1/ko active IP Right Grant
- 2011-08-23 EP EP18199427.8A patent/EP3443985B1/en active Active
- 2011-08-23 AU AU2011293554A patent/AU2011293554B9/en active Active
- 2011-08-23 US US13/215,464 patent/US10294296B2/en active Active
- 2011-08-23 RU RU2013110030/15A patent/RU2013110030A/ru unknown
- 2011-08-23 EP EP16165736.6A patent/EP3075394B1/en active Active
- 2011-08-23 KR KR1020137007024A patent/KR20130108305A/ko active Application Filing
- 2011-08-23 KR KR1020177026757A patent/KR101910760B1/ko active IP Right Grant
- 2011-08-23 KR KR1020167013067A patent/KR20160062200A/ko active Application Filing
- 2011-08-23 WO PCT/US2011/048747 patent/WO2012027324A2/en active Application Filing
- 2011-08-23 SG SG2013011242A patent/SG187853A1/en unknown
- 2011-08-23 CN CN201710556357.1A patent/CN107281488B/zh active Active
- 2011-08-23 MX MX2013002160A patent/MX342776B/es active IP Right Grant
- 2011-08-23 KR KR1020187029749A patent/KR102104296B1/ko active IP Right Grant
- 2011-08-23 ES ES11820492.4T patent/ES2622482T3/es active Active
-
2013
- 2013-02-25 ZA ZA2013/01420A patent/ZA201301420B/en unknown
-
2016
- 2016-03-30 PH PH12016500578A patent/PH12016500578A1/en unknown
- 2016-05-19 JP JP2016100753A patent/JP6917681B2/ja active Active
-
2018
- 2018-11-07 IL IL262856A patent/IL262856B/en active IP Right Grant
- 2018-12-20 US US16/228,060 patent/US11932688B2/en active Active
-
2019
- 2019-07-05 JP JP2019125907A patent/JP7316120B2/ja active Active
-
2020
- 2020-06-14 IL IL275350A patent/IL275350B/en unknown
-
2021
- 2021-06-09 JP JP2021096528A patent/JP2021138750A/ja active Pending
-
2023
- 2023-08-11 US US18/448,526 patent/US20230382989A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013536236A5 (ja) | ||
IL214255B (en) | Use of antibodies for the preparation of drugs for the treatment of cancer associated with tumor antigen and methods for diagnosing cancer associated with tumor antigen | |
NZ719368A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
NZ703481A (en) | Cd37-binding molecules and immunoconjugates thereof | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
JP2014512354A5 (ja) | ||
JP2014508752A5 (ja) | ||
JP2014509659A5 (ja) | ||
EP3064509A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
IN2015DN00450A (ja) | ||
NZ741615A (en) | Treatment of brain cancer | |
RU2013110030A (ru) | Лечение неопластических заболеваний | |
RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
TWD162792S (zh) | 粒子線治療機器用放射線照射器 | |
EA201691385A1 (ru) | Комбинированная терапия рака | |
JP2013544892A5 (ja) | ||
TWD164871S (zh) | 粒子線治療機器用放射線照射器 | |
JP2015531397A5 (ja) | ||
NZ628454A (en) | Combination therapy of anti-mif antibodies and glucocorticoids | |
NZ625758A (en) | Method for treating breast cancer | |
Howell | Second primary cancers and cardiovascular disease after radiation therapy. NCRP report no. 170 | |
MX2012001745A (es) | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. |